Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prelude Therapeutics Incorporated - Common Stock
(NQ:
PRLD
)
3.230
UNCHANGED
Streaming Delayed Price
Updated: 12:59 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prelude Therapeutics Incorporated - Common Stock
< Previous
1
2
3
4
5
Next >
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Why Did PRLD Stock Surge 13% Today?
↗
February 03, 2026
Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396.
Via
Stocktwits
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
February 03, 2026
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
December 06, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
November 26, 2025
From
Schall Law
Via
GlobeNewswire
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
November 19, 2025
From
Schall Law
Via
GlobeNewswire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END
Via
FinancialNewsMedia
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From
FN Media Group LLC
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 13, 2025
Via
Benzinga
Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway
↗
November 12, 2025
Prelude Therapeutics beats Q3 2025 earnings estimates, extends cash runway into 2027, and advances its precision oncology pipeline.
Via
Chartmill
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
November 11, 2025
From
The Schall Law Firm
Via
Business Wire
In today's session, these stocks are experiencing unusual volume.
↗
November 05, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Tuesday?
↗
November 04, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look.
↗
November 04, 2025
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via
Chartmill
Tuesday's session: top gainers and losers
↗
November 04, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 04, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
November 04, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates
↗
November 04, 2025
Via
Benzinga
Topics
Stocks
Tuesday's pre-market session: top gainers and losers
↗
November 04, 2025
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 04, 2025
Via
Benzinga
Prelude Therapeutics Announces Strategic Business Update
November 04, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
November 04, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
These stocks are moving in today's after hours session
↗
November 03, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 03, 2025
Via
Benzinga
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
November 03, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Tuesday's session: top gainers and losers
↗
October 21, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
October 17, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
